<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oncology Product Guide &#187; Colon Cancer</title>
	<atom:link href="http://www.oncologyproductguide.com/blog/category/colon-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.oncologyproductguide.com/blog</link>
	<description>A comprehensive guide to oncology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:00:01 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Teva receives approval for generic Eloxatin</title>
		<link>http://www.oncologyproductguide.com/blog/2009/08/12/teva-receives-approval-for-generic-eloxatin/</link>
		<comments>http://www.oncologyproductguide.com/blog/2009/08/12/teva-receives-approval-for-generic-eloxatin/#comments</comments>
		<pubDate>Thu, 13 Aug 2009 04:09:13 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Colon Cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Eloxatin]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[oxaliplatin]]></category>
		<category><![CDATA[Teva Pharma]]></category>

		<guid isPermaLink="false">http://www.oncologyproductguide.com/blog/?p=118</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd began selling a generic injectable version of Eloxatin, a chemotherapy drug, after the approval of the FDA. The oxaliplatin drug is available in 50 mg and 100 mg dosage. The US sales of Eloxatin totaled $1.3 billion in 2008 and the drug is approved to treat advanced colon cancer and stage [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.oncologyproductguide.com/blog/wp-content/uploads/2009/08/Teva.png"><img class="alignright size-full wp-image-119" style="margin: 5px" src="http://www.oncologyproductguide.com/blog/wp-content/uploads/2009/08/Teva.png" alt="Teva" width="200" height="74" /></a>Teva Pharmaceutical Industries Ltd began selling a generic injectable version of Eloxatin, a chemotherapy drug, after the approval of the FDA. The oxaliplatin drug is available in 50 mg and 100 mg dosage. The US sales of Eloxatin totaled $1.3 billion in 2008 and the drug is approved to treat advanced colon cancer and stage III colon cancer following surgery.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.oncologyproductguide.com/blog/2009/08/12/teva-receives-approval-for-generic-eloxatin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
